Catalent, Inc. CTLT recently executed a development and license agreement with Ethicann Pharmaceuticals Inc. to develop Ethicann’s clinical drug pipeline using its proprietary Zydis orally ...
Study Confirms MDMA Is Stable on Zydis(R) ODT and Suitable for Pre-Gastric Absorption Toronto, Ontario--(Newsfile Corp. - October 4, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: ...
Toronto, Ontario--(Newsfile Corp. - February 9, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a biotechnology company developing therapeutics to treat addiction ...
This article is part of PharmTech's supplement "API Synthesis and Formulation 2009." New drug-delivery technologies are often championed by contract manufacturing organizations. For new technologies ...
CAMBRIDGE, England--(BUSINESS WIRE)--Cycle Pharmaceuticals Ltd (Cycle) is pleased to announce that it has signed an agreement with Catalent, Inc. (Catalent) (NYSE: CTLT), to develop innovative ...
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it is to ...
We believe that the Zydis ODT delivery technology, when incorporated into our MM-120 product candidate, represents an optimized pharmaceutical product that has the potential to enhance our competitive ...
DALLAS & FORT WORTH, Texas--(BUSINESS WIRE)--Neos Therapeutics, Inc. (NASDAQ: NEOS), a pharmaceutical company with a late‐stage pipeline of innovative extended-release (“XR”) product candidates for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback